Studies by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have demonstrated that common alleles in RAD51, FGFR2, MAP3K1, TOX3/TNRC9, LSP1, SLC4A7/NEK10, a 2q35 locus and a 5p12 locus affect breast cancer risk in BRCA2 mutation carriers [ 18- 20].
Several clinical studies have demonstrated that leukotriene modifiers are capable of protecting inflamed airways against constriction induced by different spasmogens, reducing asthma symptoms and exacerbations, as well as the need for use of rescue bronchodilators, and decreasing the level of airway inflammation.
Genome-wide and exomic sequencing data from recent years have demonstrated that mutations in epigenetic modifiers comprise a large portion of all genetic events in many cancers, including tumors such as renal carcinoma, adenoid cystic carcinoma (ACC), and transitional cell carcinoma (TCC) of the bladder (Dalgliesh et al., 2010; Gui et al., 2011; Ho et al., 2013).
Recent studies using the Aire knockout mouse have demonstrated gene-dose dependency and disease modifier loci, returning the onus of exploration to human genetics.
We have demonstrated that sex is a critical modifier of the correlation between the CD4+ T cell transcriptome and IgE, and suggest that such sex-specific modification should be consideration in future studies of IgE.
A number of case studies and a handful of randomized trials have demonstrated the potential toxicities with the use of biologic response modifiers.
We have demonstrated that FAD evolves regardless of its effect on the population mean fitness, because FAD modifier alleles become associated with good genetic backgrounds (abandon-ship effect).
Now you have demonstrated.
Many Poles and Swedes have demonstrated.
